Human Genetics · 2007 · 142 citations · 24 references
Life SciencesGeneticsMolecular GeneticsHuman GeneticsMedical GeneticsNeuromuscular DisordersGenetic DisordersGenetic SyndromesMendelian DisordersMendelian Neurological DisordersMuscular DystrophyNeurogenetic DisordersCongenital Disorders Of GlycosylationCongenital Glycosylation DisordersGlycosylation DefectsMuscular Dystrophy GeneticsMuscular Dystrophy PathophysiologyNeuromuscular DevelopmentNeuromuscular DysfunctionStructural Brain Abnormalities
Intragenic homozygous deletions in the Large gene are associated with a severe neuromuscular phenotype in the myodystrophy (myd) mouse. These mutations result in a virtual lack of glycosylation of alpha-dystroglycan. Compound heterozygous LARGE mutations have been reported in a single human patient, manifesting with mild congenital muscular dystrophy (CMD) and severe mental retardation. These mutations are likely to retain some residual LARGE glycosyltransferase activity as indicated by residual alpha-dystroglycan glycosylation in patient cells. We hypothesized that more severe LARGE mutations are associated with a more severe CMD phenotype in humans. Here we report a 63-kb intragenic LARGE deletion in a family with Walker-Warburg syndrome (WWS), which is characterized by CMD, and severe structural brain and eye malformations. This finding demonstrates that LARGE gene mutations can give rise to a wide clinical spectrum, similar as for other genes that have a role in the post-translational modification of the alpha-dystroglycan protein.
24
Daniel Beltrán-Valero de Bernabé, Sophie Currier, Alice Steinbrecher et al. · The American Journal of Human Genetics · 2002 · 688 citations · Full text